Addressing Itch and Quality of Life for Patients With Atopic Dermatitis

By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.

Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.

Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.